2014 CME Symposia - CME Breakfast Symposium C

Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!

Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.

CME Breakfast Symposium C

Friday · 6:15 - 7:45am

New Targets and Treatments for LDL Lowering: Role of PCSK9 Inhibitors

Supported by an educational grant from Amgen

Symposium Overview

Hypercholesterolemia is a major risk factor for cardiovascular diseases, increasing the incidence of myocardial infarction and death. However, patients on statin therapy who fail to reach their LDL-C treatment goal due to intolerance, poor therapeutic response, or severe familial hypercholesterolemia have few effective therapeutic options. Recent genetic insights have revealed novel therapeutic mechanisms that provide further LDL-C reductions on top of statin therapy. PCSK9 inhibitors are an emerging drug class designed to target and suppress the PCSK9 protein that prevents the body from removing LDL cholesterol from the bloodstream.

This symposium will elucidate the PCSK9 pathway and the importance of LDL receptor recycling in the regulation of cholesterol homeostasis, and expert faculty will summarize the latest clinical efficacy and safety data on PCSK9 inhibitors in development. Finally, a forward-looking panel discussion will explore how these novel therapies could potentially be integrated into the management of patients with severe lipid disorders to help achieve treatment goals and reduce cardiovascular risk.

Learning Objectives

  • Appraise recent guidelines on lipid management and strategies for management of individuals with severe and/or resistant hypercholesterolemia.
  • Examine the need for additional LDL-C-lowering therapies beyond current statin-based therapy as a strategy for addressing residual CV risk in patients with familial or resistant hypercholesterolemia, and/or statin intolerance.
  • Review the pathogenesis of atherosclerosis, the PCSK9 pathway and importance of LDL receptor recycling in the cholesterol homeostasis.
  • Explore the mechanisms and potential applications of emerging PCSK9-based therapies for LDL-C reduction and the rationale for the use of monoclonal antibodies.
  • Compare and evaluate evidence from recent clinical trials of PCSK9 inhibitors and assess their impact on lipids and cardiovascular risk.

Preliminary Agenda & Faculty

6:15 - 6:20am Introduction and Opening Remarks Chairperson: Christie M. Ballantyne, MD
6:20 - 6:40am LDL-C Focused Cardioprotection: What Do Recent Trials and Global Lipid Guidelines Tell Us? Presenter: James A. Underberg, MD
6:40 - 7:00am Translating Genetic Discoveries into Novel Targets for Lipid Management Presenter: Michael H. Davidson, MD
7:00 - 7:20am PCSK9 Inhibitors: Mechanistic Insights and Clinical Evidence for a New Therapeutic Approach to LDL-C Lowering Presenter: Marc S. Sabatine, MD, MPH
7:20 - 7:45am The Roadmap of PCSK9 Inhibitors to the Clinic: Panel Discussion and Q&A Moderator: Christie M. Ballantyne, MD
Presenters & discussants: Michael H. Davidson, MD; Marc. S. Sabatine, MD, MPH; James A. Underberg, MD

Christie M. Ballantyne, MD

  • Professor of Medicine
  • Chief, Section of Cardiovascular Research
  • Chief, Section of Cardiology
  • Department of Medicine, Baylor College of Medicine
  • Director, Center for Cardiovascular Disease Prevention
  • Baylor College of Medicine
  • Methodist DeBakey Heart Center
  • Houston, TX

Michael H. Davidson, MD

  • Clinical Professor
  • Director of the Lipid Clinic
  • The University of Chicago
  • Pritzker School of Medicine
  • Chicago, IL

Marc S. Sabatine, MD, MPH

  • Chairman, TIMI Study Group
  • Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine
  • Brigham and Women's Hospital
  • Professor of Medicine
  • Harvard Medical School
  • Boston, MA

James A. Underberg, MD

  • Lipidology & Cardiovascular Disease Prevention
  • Clinical Assistant Professor of Medicine
  • NYU Medical School & NYU Center for CV Prevention
  • Director, Bellevue Hospital Lipid Clinic
  • President-Elect National Lipid Association
  • New York, NY

View Complete Accreditation Details and Program Overview: CMHC Accreditation